Incidence and Risk Stratification of Hepatitis B Reactivation With Anti-CD38 Therapy

13 Feb 20264 min read0 viewsJournal Feed

GIST (Key Takeaways)

Recently updated European Association for the Study of the Liver (EASL) clinical practice guidelines highlight the importance of nucleos(t)ide analogue (NA) prophylaxis in patients with risk of reactivation.[1] Risk factors include B-cell–depleting agents such as rituximab,[2] T-cell–modulating treatments, several cytokine-targeting regimens, and combination immune-modifying therapies.
These recommendations highlight the broad vulnerability of patients exposed to intensive or prolonged immunosuppression.